Amarin Corp ADR (AMRN)

$14.25 -0.11 (-0.77%)
Market Cap 301.12M
Revenue (ttm) 213.65M
Net Income (ttm) -38.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -18.16%
Debt to Equity Ratio 0.00
Volume 20,227
Avg Vol 80,574
Day's Range N/A - N/A
Shares Out 20.97M
Stochastic %K 74%
Beta 0.81
Analysts Hold
Price Target $14.00

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 353 0 166 99020
Address:
One Central Plaza, 8th Floor 36 Dame Street, Dublin, Ireland
NebulaArb
NebulaArb Aug. 10 at 3:30 PM
$AMRN $POET $AXON $INTC $SSPC Amarin remains focused on cardiovascular therapies, POET develops optical interconnects for AI infrastructure, Axon benefits from public-safety technology spending, Intel remains focused on semiconductor manufacturing recovery, and SSPC remains speculative. I'm watching prescription growth, AI infrastructure, government contracts, chip demand, and funding.
1 · Reply
NotAgain2024
NotAgain2024 Aug. 10 at 2:43 PM
$AMRN Yes very good, AMRN already stole 99,92% so this is for sure a better investment.
0 · Reply
DoMoreCharity
DoMoreCharity Aug. 10 at 2:18 PM
$AMRN Smartkarma is a subscription platform for Asia-Pacific institutional desks.
0 · Reply
BobGood
BobGood Aug. 10 at 2:17 PM
$AMRN $AMRN Another heart drug failure today — TENX. TENX went from around $13.50 to $1.48, wiping out roughly 90% of its value after the pivotal study failed. IMHO, VASCEPA remains a potentially valuable cardiovascular drug that is still being overlooked by many — including Big Pharma. While others are facing clinical failures, I’m still waiting for that good news from AMRN one early morning. 🚀 Let’s see what happens. GL
0 · Reply
DerErsteAmnesius
DerErsteAmnesius Aug. 10 at 1:44 PM
$AMRN It makes no sense to wait around between the quarterly earnings announcements to see if anything happens here... why would it?
0 · Reply
DoMoreCharity
DoMoreCharity Aug. 10 at 1:24 PM
$AMRN https://www.smartkarma.com/insights/primer-amarin-corporation-plc-amrn-us-aug-2026#
0 · Reply
DoMoreCharity
DoMoreCharity Aug. 10 at 1:12 PM
$AMRN https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177861046
0 · Reply
NotAgain2024
NotAgain2024 Aug. 10 at 11:19 AM
$AMRN Ready for another week of nothing! wuhhuuu
0 · Reply
invest2992
invest2992 Aug. 9 at 9:20 PM
$AMRN market risk index. https://drive.google.com/file/d/1CxPYqOXwVkieAjxVoE40TvUr_7cQbhcT/view?usp=drivesdk
0 · Reply
DoMoreCharity
DoMoreCharity Aug. 9 at 4:37 PM
$AMRN “No fixed deadline” — soft deadline exists. Under 35 U.S.C. §154(b)(1)(A)(ii), if the USPTO doesn’t act within 4 months of the applicant’s reply, Patent Term Adjustment starts accruing day-for-day. Response filed June 3 -> that clock hits ~October 3, 2026.
0 · Reply
Latest News on AMRN
Amarin Corporation Transcript: Transcript

Aug 4, 2026, 11:41 PM EDT - 5 days ago

Amarin Corporation Transcript: Transcript

Amarin Corporation Slides

Jul 30, 2026, 4:08 AM EDT - 11 days ago

Amarin Corporation Slides

Amarin Corporation Quarterly report

Jul 29, 2026, 4:31 PM EDT - 11 days ago

Amarin Corporation Quarterly report

Amarin Corporation Earnings release

Jul 29, 2026, 7:19 AM EDT - 12 days ago

Amarin Corporation Earnings release

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Jul 29, 2026, 7:00 AM EDT - 12 days ago

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

Jul 15, 2026, 8:00 AM EDT - 26 days ago

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

Amarin Corporation Transcript: Transcript

Jul 8, 2026, 3:21 PM EDT - 4 weeks ago

Amarin Corporation Transcript: Transcript

Amarin Corporation Transcript: Transcript

Jul 8, 2026, 12:06 PM EDT - 4 weeks ago

Amarin Corporation Transcript: Transcript

Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape

Jun 30, 2026, 4:15 PM EDT - 5 weeks ago

Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia

May 27, 2026, 8:00 AM EDT - 2 months ago

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia

Amarin Corporation Transcript: Transcript

Apr 29, 2026, 10:05 AM EDT - 3 months ago

Amarin Corporation Transcript: Transcript

Amarin Reports 2026 First Quarter Financial Results

Apr 29, 2026, 7:00 AM EDT - 3 months ago

Amarin Reports 2026 First Quarter Financial Results

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

Apr 15, 2026, 8:00 AM EDT - 4 months ago

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

Amarin highlights new recommendation for treatment of CV risk

2026-03-18T12:41:54.000Z - 5 months ago

Amarin highlights new recommendation for treatment of CV risk

Amarin to present data in patients at extreme cardiovascular risk

2026-03-16T12:27:24.000Z - 5 months ago

Amarin to present data in patients at extreme cardiovascular risk

Amarin highlights recent data published on REDUCE-IT study

2026-03-02T13:26:30.000Z - 5 months ago

Amarin highlights recent data published on REDUCE-IT study

Amarin CFO says ‘well positioned’ to deliver on 2026 strategic priorities

2026-02-25T12:14:50.000Z - 5 months ago

Amarin CFO says ‘well positioned’ to deliver on 2026 strategic priorities

Amarin issues call to action for American Heart Month

2026-02-23T13:23:34.000Z - 6 months ago

Amarin issues call to action for American Heart Month

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

Feb 23, 2026, 8:00 AM EST - 6 months ago

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

US Supreme Court to hear 'skinny label' patent fight involving Amarin

Jan 16, 2026, 2:44 PM EST - 7 months ago

US Supreme Court to hear 'skinny label' patent fight involving Amarin

Amarin comments on recent innovations for patients with elevated triglycerides

2026-01-09T12:13:43.000Z - 7 months ago

Amarin comments on recent innovations for patients with elevated triglycerides

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

Jan 9, 2026, 7:00 AM EST - 7 months ago

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

Amarin expects Q4 net revenue $48M-$43M

2026-01-08T12:06:26.000Z - 7 months ago

Amarin expects Q4 net revenue $48M-$43M

Amarin announces new post hoc analysis of aspirin use in REDUCE-IT

2025-11-10T00:10:10.000Z - 9 months ago

Amarin announces new post hoc analysis of aspirin use in REDUCE-IT

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Nov 9, 2025, 4:15 PM EST - 9 months ago

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

Nov 3, 2025, 8:30 AM EST - 10 months ago

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

Amarin reports Q3 EPS (2c) vs (6c) last year

2025-10-29T11:11:18.000Z - 10 months ago

Amarin reports Q3 EPS (2c) vs (6c) last year

Amarin issues statement related to recent action by FDA for fenofibrate drugs

2025-10-27T12:05:31.000Z - 10 months ago

Amarin issues statement related to recent action by FDA for fenofibrate drugs

Amarin, HLS Therapeutics present REDUCE-IT, EPA mechanistic data

2025-10-14T12:10:55.000Z - 10 months ago

Amarin, HLS Therapeutics present REDUCE-IT, EPA mechanistic data

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

Oct 14, 2025, 8:00 AM EDT - 10 months ago

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

Amarin presents new REDUCE-IT analyses

2025-09-01T12:30:11.000Z - 1 year ago

Amarin presents new REDUCE-IT analyses

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

Aug 31, 2025, 8:30 AM EDT - 1 year ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Aug 30, 2025, 8:30 AM EDT - 1 year ago

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Amarin announces upcoming presentations at ESC Congress 2025

2025-08-25T12:05:06.000Z - 1 year ago

Amarin announces upcoming presentations at ESC Congress 2025

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

Aug 25, 2025, 8:00 AM EDT - 1 year ago

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

Amarin expects accelerated in-market demand in Europe

2025-07-30T11:11:52.000Z - 1 year ago

Amarin expects accelerated in-market demand in Europe

Amarin Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 7:00 AM EDT - 1 year ago

Amarin Reports Second Quarter 2025 Financial Results

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

Jul 23, 2025, 7:30 AM EDT - 1 year ago

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

Amarin announces exclusive license, supply agreement with Recordati

2025-06-24T11:05:33.000Z - 1 year ago

Amarin announces exclusive license, supply agreement with Recordati

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

Jun 24, 2025, 7:05 AM EDT - 1 year ago

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

Amarin regains compliance with Nasdaq

2025-04-29T20:40:18.000Z - 1 year ago

Amarin regains compliance with Nasdaq

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 29, 2025, 4:15 PM EDT - 1 year ago

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 28, 2025, 4:15 PM EDT - 1 year ago

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 9, 2025, 7:30 AM EDT - 1 year ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Apr 7, 2025, 7:30 AM EDT - 1 year ago

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Mar 19, 2025, 12:45 PM EDT - 1 year ago

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Mar 19, 2025, 7:30 AM EDT - 1 year ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Feb 27, 2025, 9:00 AM EST - 1 year ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Feb 19, 2025, 8:30 AM EST - 1 year ago

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 16, 2024, 7:00 AM EST - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Amarin Appoints Peter Fishman Chief Financial Officer

Dec 13, 2024, 9:00 AM EST - 1 year ago

Amarin Appoints Peter Fishman Chief Financial Officer

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Sep 9, 2024, 7:30 AM EDT - 2 years ago

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Aug 22, 2024, 8:30 AM EDT - 2 years ago

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 31, 2024, 7:00 AM EDT - 2 years ago

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Jul 17, 2024, 4:15 PM EDT - 2 years ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Jul 17, 2024, 8:00 AM EDT - 2 years ago

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Jul 8, 2024, 7:30 AM EDT - 2 years ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Jun 7, 2024, 7:16 PM EDT - 2 years ago

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Amarin Board of Directors Announces CEO Transition

Jun 4, 2024, 7:30 AM EDT - 2 years ago

Amarin Board of Directors Announces CEO Transition

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

May 28, 2024, 8:15 AM EDT - 2 years ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 6, 2024, 8:00 AM EDT - 2 years ago

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Amarin Reports First Quarter 2024 Business Update and Financial Results

May 1, 2024, 7:00 AM EDT - 2 years ago

Amarin Reports First Quarter 2024 Business Update and Financial Results

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Apr 24, 2024, 2:00 PM EDT - 2 years ago

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Amarin Announces Results of Annual General Meeting of Shareholders

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Amarin Announces Results of Annual General Meeting of Shareholders

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Apr 6, 2024, 3:30 PM EDT - 2 years ago

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 29, 2024, 7:00 AM EST - 2 years ago

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

Feb 15, 2024, 8:00 AM EST - 2 years ago

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

Amarin Chairman & CEO Issue Letter to Shareholders

Jan 22, 2024, 7:30 AM EST - 2 years ago

Amarin Chairman & CEO Issue Letter to Shareholders

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

Jan 10, 2024, 7:00 AM EST - 2 years ago

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

NebulaArb
NebulaArb Aug. 10 at 3:30 PM
$AMRN $POET $AXON $INTC $SSPC Amarin remains focused on cardiovascular therapies, POET develops optical interconnects for AI infrastructure, Axon benefits from public-safety technology spending, Intel remains focused on semiconductor manufacturing recovery, and SSPC remains speculative. I'm watching prescription growth, AI infrastructure, government contracts, chip demand, and funding.
1 · Reply
NotAgain2024
NotAgain2024 Aug. 10 at 2:43 PM
$AMRN Yes very good, AMRN already stole 99,92% so this is for sure a better investment.
0 · Reply
DoMoreCharity
DoMoreCharity Aug. 10 at 2:18 PM
$AMRN Smartkarma is a subscription platform for Asia-Pacific institutional desks.
0 · Reply
BobGood
BobGood Aug. 10 at 2:17 PM
$AMRN $AMRN Another heart drug failure today — TENX. TENX went from around $13.50 to $1.48, wiping out roughly 90% of its value after the pivotal study failed. IMHO, VASCEPA remains a potentially valuable cardiovascular drug that is still being overlooked by many — including Big Pharma. While others are facing clinical failures, I’m still waiting for that good news from AMRN one early morning. 🚀 Let’s see what happens. GL
0 · Reply
DerErsteAmnesius
DerErsteAmnesius Aug. 10 at 1:44 PM
$AMRN It makes no sense to wait around between the quarterly earnings announcements to see if anything happens here... why would it?
0 · Reply
DoMoreCharity
DoMoreCharity Aug. 10 at 1:24 PM
$AMRN https://www.smartkarma.com/insights/primer-amarin-corporation-plc-amrn-us-aug-2026#
0 · Reply
DoMoreCharity
DoMoreCharity Aug. 10 at 1:12 PM
$AMRN https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177861046
0 · Reply
NotAgain2024
NotAgain2024 Aug. 10 at 11:19 AM
$AMRN Ready for another week of nothing! wuhhuuu
0 · Reply
invest2992
invest2992 Aug. 9 at 9:20 PM
$AMRN market risk index. https://drive.google.com/file/d/1CxPYqOXwVkieAjxVoE40TvUr_7cQbhcT/view?usp=drivesdk
0 · Reply
DoMoreCharity
DoMoreCharity Aug. 9 at 4:37 PM
$AMRN “No fixed deadline” — soft deadline exists. Under 35 U.S.C. §154(b)(1)(A)(ii), if the USPTO doesn’t act within 4 months of the applicant’s reply, Patent Term Adjustment starts accruing day-for-day. Response filed June 3 -> that clock hits ~October 3, 2026.
0 · Reply
declanaidan
declanaidan Aug. 8 at 6:05 PM
$AMRN Amarin good, Red Sox good, beer good Hoping Amarin has quick, epic turnaround like Sox. Worst team in baseball end of June
1 · Reply
DoMoreCharity
DoMoreCharity Aug. 8 at 12:55 PM
$AMRN https://www.linkedin.com/posts/ahsan-ul-hasnat_cardiology-cardiovascularmedicine-icosapentethyl-share-7489729198442369024-kh6D/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAappXEBEo5xWglK2bmEx478x0aaRWW4o7I
0 · Reply
DoMoreCharity
DoMoreCharity Aug. 8 at 11:55 AM
$AMRN https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177857793
0 · Reply
NotAgain2024
NotAgain2024 Aug. 8 at 11:22 AM
$AMRN loser company, loser mgmt
1 · Reply
DoMoreCharity
DoMoreCharity Aug. 8 at 11:13 AM
$AMRN Omega-3 fatty acids and oral and systemic inflammation A secondary analysis of a randomized trial in patients with coronary artery disease https://jada.ada.org/article/S0002-8177(25)00757-3/abstract?dgcid=PromoSpots_ADAorg_ADANews_AugustJADA&fbclid=IwVERDUATj7rJwZG9mAWZkaWQWUMHJp9Fv_U7ZmaRsZU8Et_XwQdXJOGV4dG4DYWVtAjExAHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR4_f0w83Y8tKxNH-caNTf0IGRGqFUJRengq2hVe44RwiduzK_55dViHZB_WuQ_aem_X4OSQIL5sN4zUerMQwpuBA
0 · Reply
DoMoreCharity
DoMoreCharity Aug. 8 at 11:11 AM
$AMRN https://www.facebook.com/share/p/1HbRtHUadp/?mibextid=wwXIfr
0 · Reply
DoMoreCharity
DoMoreCharity Aug. 8 at 9:28 AM
$AMRN https://www.holdingschannel.com/aum/sarissa-capital-management-lp-aum/
0 · Reply
DoMoreCharity
DoMoreCharity Aug. 8 at 1:12 AM
$AMRN Reminder Steven Ketchum “Beyond supporting current commercialization efforts, we continue to evaluate cost-effective opportunities to further advance the science of icosapent ethyl and explore potential future life cycle management initiatives. While these efforts remain in the early stages and no development decisions have been made that are appropriate for public disclosure today, we believe disciplined scientific innovation remains an important component of long-term value creation. We will communicate developments when there are meaningful updates to share without setting unrealistic expectations.”
0 · Reply
Md80dog
Md80dog Aug. 7 at 3:17 PM
$AMRN anyone here remember when Puerto Rico was on this list?
1 · Reply
VascepaBID
VascepaBID Aug. 7 at 2:57 PM
$AMRN What do we do about the American market? What happened to the combo drug? Everything was put on hold because of the patent case and now that pathway has been exhausted and still no news on the next move.
1 · Reply
CaptBeer
CaptBeer Aug. 7 at 12:55 PM
$AMRN VAZKEPA: Commercialized and Reimbursed in 11 European Countries. Expanding access. Improving Outcomes. Saving Lives!
2 · Reply